Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.
In MVOR-1, 65% of patients treated with Emrosi achieved IGA success at week 16 compared with 46% of the doxycycline group (treatment difference, 18% [95% CI, 5-31]) and 31% of the placebo group ...
The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...
Results The prevalence of UI was 45.3% (n=39), with the average impact on quality of life scored at 6.1±3.5 on ... Drafting the work or reviewing it critically for important intellectual content: PNB, ...
Following the recent Monetary Policy Rate (MPR) increase to 26.25 per cent by the Monetary Policy Committee (MPC) of the Central Bank of Nigeria (CBN), 11 deposit money banks (DMBs) have announced ...